LEVODOPA CAP,INHL
Clinical Criteria Summary
Exclusion Criteria
- Concomitant use of a nonselective monoamine oxidase inhibitor (MAOI), such as phenelzine or tranylcypromine (must be >14 days post discontinuing therapy)
- Asthma or chronic obstructive pulmonary disease (COPD)
- Presence of psychotic disorder
- Glaucoma with uncontrolled intraocular pressure (IOP)
Inclusion Criteria
- Patient is under the care of a VA/VA-authorized Neurologist or locally designated expert who is responsible for prescribing and monitoring therapy
- Patient has Parkinson’s Disease and is receiving at least four times daily carbidopa/levodopa
- Patient will continue to receive oral carbidopa/levodopa therapy
- Patient has OFF time of >2 hours/day
- Contraindication to or inadequate therapeutic response to use of a dopamine agonist, catechol-O-methyl transferase [COMT] inhibitor, monoamine oxidase type B [MAO B] inhibitor, ER capsule formulation or CR tablet formulation
- Attempts to reduce dosing intervals have not adequately resolved OFF periods